Clinical Study on Track to Meet Primary Endpoints with Interim Data Demonstrating Blood-Based Assay Capable of Predicting Relapse Risk Through Analysis of Genomic Instability and Telomere Architecture
Vancouver, British Columbia--(Newsfile Corp. - July 16, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the 3D analysis of telomeres (which are the ends of chromosomes), announced positive interim results from an ongoing retrospective clinical study conducted in collaboration with National and Kapodistrian University of Athens. The clinical trial, which is expected to conclude in summer 2026, analyzes baseline blood samples from multiple myeloma patients treated with standard-of-care regimens. The study cohort includes patients with known two-year clinical outcomes, enabling direct comparisons between patients who relapsed and those who remained in remission.
The interim analysis evaluated diagnostic blood samples from 50 multiple myeloma patients with sufficient follow-up data. The study identified "Average Distance to Nuclear Center," a telomere-associated nuclear architecture parameter linked to genomic instability, as the strongest predictor of relapse status. Receiver Operating Characteristic (ROC) analysis demonstrated strong discriminatory performance, with the assay achieving an Area Under the Curve (AUC) of 0.849, a level considered highly predictive in clinical diagnostics
"These interim results support our belief that telomere-driven genomic instability analysis may provide clinicians with a fundamentally new way to assess relapse risk in multiple myeloma," said John Farlinger, CEO and Chairman of Telo Genomics. "Current monitoring approaches are valuable for measuring disease burden, but do not fully address the challenge of identifying which patients are most likely to experience relapse. We believe our platform can help fill that gap, representing a significant opportunity in multiple myeloma and, potentially, multiple other cancers as well as Alzheimer's disease."
"These results provide preliminary evidence that the Telo Genomics platform can deliver liquid-biopsy-based prognostic information," said Dr. Sabine Mai, Co-Founder and Director of Telo Genomics. "Current MRD approaches, including EuroFlow-based next-generation flow cytometry and Adaptive Biotechnologies' ClonoSEQ® assay, provide valuable information regarding residual disease burden, but are not designed to assess the biological characteristics that may drive future relapses. By evaluating genomic instability through three-dimensional telomere organization at the single-cell level, our platform may provide prognostic insight into relapse risk that complements existing MRD methodologies."